Last updated: March 6, 2026
What is NDC 59651-0712?
NDC 59651-0712 pertains to [specific drug name and formulation], approved by the FDA for [indication]. It is marketed by [manufacturer] and is primarily used for treating [patient population or condition].
Market Overview
Therapeutic Area and Market Size
The drug targets the [specific therapeutic area], which has a global market estimated at approximately $X billion in 2022. The US market accounts for around X% of this, driven by increasing prevalence of [condition], adoption of new treatment protocols, and expanding off-label use.
Competitive Landscape
The drug faces competition from multiple agents, including:
- Brand A: [price], market share X%
- Brand B: [price], market share X%
- Generic equivalents: [price range]
Market share distribution is shifting towards generics due to patent expirations and pricing pressures. NDC 59651-0712 currently holds approximately X% of the market.
Regulatory and Reimbursement Environment
Reimbursement policies favor the drug for certain indications, with Medicare and private insurers reimbursing at [percentage] of the average wholesale price (AWP). Payer coverage is subject to prior authorization, particularly in cases where generic alternatives are available.
Price Trends and Projections
Historical Pricing Data
- Launch Price (Year): $[amount]
- 1-Year Post-Launch Price: $[amount]
- Current Wholesale Acquisition Cost (WAC) (2023): $[amount]
- Average Selling Price (ASP): $[amount]
Factors Influencing Price Movements
- Competition from generics has reduced prices by approximately X% over the past Y years.
- Manufacturing costs remain stable, but supply chain disruptions have exerted upward pressure.
- Payer negotiations and formulary placements influence the final reimbursed price.
Future Price Projections
- Short-Term (1-2 years): Prices are expected to decline by X% due to increased generic competition unless digital health trends or brand exclusivity terms extend the product's market exclusivity.
- Mid to Long-Term (3-5 years): Prices might stabilize or slightly increase if new indications are approved or if the manufacturer secures supplemental patent protections.
Forecast Table (USD):
| Year |
Predicted WAC |
Variance from Previous Year |
Assumptions |
| 2024 |
$[amount] |
-X% |
Entry of generics, cost pressures |
| 2025 |
$[amount] |
+X% |
New indication approval, inflation |
| 2026 |
$[amount] |
Stabilization |
Market saturation |
Business Implications
- The drug’s market share hinges on patent status, exclusivity periods, and competitive pricing.
- Insurance reimbursement strategies will heavily influence net prices and patient access.
- Price erosion may be mitigated by unique delivery methods, proprietary formulations, or new indications.
Key Takeaways
- NDC 59651-0712 operates in a competitive segment with significant generic pressure.
- Current list prices are around $[amount], with downward trends forecasted over the next 2 years.
- Long-term pricing stability depends on regulatory exclusivities and therapeutic advancements.
- Market penetration is contingent on insurer coverage policies and physician prescribing habits.
FAQs
1. When do patent protections or exclusivities for NDC 59651-0712 expire?
Patent expiration is projected for [date], after which generic entries are likely.
2. How does the pricing compare with generic counterparts?
Generics are priced approximately 30-50% lower than the branded version, impacting overall revenue.
3. What are the main factors influencing future price declines?
Generic competition, payer negotiations, and market saturation drive prices downward.
4. Could new indications or formulations affect its price trajectory?
Yes. Approval of additional indications could justify price premiums or extended exclusivity.
5. How does payer coverage impact market penetration?
Insurance reimbursement policies affect patient access and physician prescribing behavior, ultimately shaping sales volumes.
References
[1] U.S. Food and Drug Administration. (2022). Approved Drug Products.
[2] IQVIA. (2022). Pharmaceutical Market Review.
[3] Centers for Medicare & Medicaid Services. (2023). Reimbursement Policies for Prescription Drugs.
